The online version of this article (https://doi.org/10.1186/s12886-018-0690-9) contains supplementary material, which is available to authorized users.
To assess the impact of unstudied societal factors for neovascular age-related macular degeneration (nAMD) on functional outcomes after anti-VEGFs.
Charts of 94 nAMD patients treated in the Monticelli-Paradis Centre, Marseille, France, were reviewed. Phone interviews were conducted to assess societal factors, including transportation, living status, daily reading and social security scheme (SSS). Primary outcome was the impact of family support and disease burden on functional improvement in nAMD.
Between baseline and month 24 (M24), 42.4% of the variability in best-corrected visual acuity (BCVA) was explained by the cumulative effect of the following societal factors: intermittent out-patient follow-up, marital status, daily reading, transportation type, commuting time. No isolated societal factor significantly correlated with ETDRS BCVA severity at M24. A trend to correlation was observed between the EDTRS score at M24 and the SSS (P = 0.076), economic burden (P = 0.075), time between diagnosis and treatment initiation (P = 0.070). A significant correlation was found for the disease burdensome on the patient (P = 0.034) and low vision rehabilitation (P = 0.014).
Societal factors could influence functional outcomes in nAMD patients treated with anti-VEGFs. They could contribute to the healing process or sustain disease progression.
Additional file 1: Raw data: categories and frequencies of each different variable and model parameter values showing the coefficients of the different categories of each variable. (ODT 6 kb)12886_2018_690_MOESM1_ESM.odt
Klaver CC, Assink JJ, van Leeuwen R, Wolfs RC, Vingerling JR, Stijnen T, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam study. Invest Ophthalmol Vis Sci. 2001;42:2237–41. PubMed
Kelly SP, Edwards R, Elton P, Mitchell P. Age related macular degeneration: smoking entails major risk of blindness. BMJ. 2003;326:1458-1459-1460. CrossRef
Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye Lond Engl. 2005;19:935–44. CrossRef
Orban T, Johnson WM, Dong Z, Maeda T, Maeda A, Sakai T, et al. Serum levels of lipid metabolites in age-related macular degeneration. FASEB J Off Publ Fed Am Soc Exp Biol. 2015;29:4579–88.
Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl. 1996;(30):101-8.
Ojeda B, Salazar A, Calahorro MJ, Dueñas M, Mico JA, de Sola H, et al. Understanding the different relationships between mood and sleep disorders in several groups of non-oncological patients with chronic pain. Curr Med Res Opin. 2017. p 1-8.
Sharma P, Morris NR, Adams L. Effect of experimental modulation of mood on perception of exertional dyspnea in healthy subjects. J Appl Physiol Bethesda Md 1985. 2016;120:114–120.
Hykin P, Chakravarthy U, Lotery A, McKibbin M, Napier J, Sivaprasad S. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clin Ophthalmol Auckl NZ. 2016;10:87–96.
Cohen SY, Dubois L, Ayrault S, Dourmad P, Delahaye-Mazza C, Fajnkuchen F, et al. Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2013;251:2499–503. CrossRef
- Influence of new societal factors on neovascular age-related macular degeneration outcomes
- BioMed Central